glp 1 mash approval GLP-1 use nearly doubled in 3 years among patients with MASH, compensated cirrhosis GLP-1 RAs for Treating Metabolic

How much loose skin you are left with depends on a few things: Amount of weight lost

Ozempic lawsuits allege that Novo Nordisk failed to adequately warn patients and prescribing physicians about serious injuries reported after use of Ozempic and other glucagon-like peptide-1 receptor agonist medications

The proportion of lean mass loss observed with GLP-1 medications appears similar to that seen with other weight loss interventions, including dietary restriction alone and bariatric surgery

doi:10.1080/14656566.2024.2436595 Mikdachi H, Dunsmoor-Su R

Patient Selection & Clinical Decision-Making When orforglipron reaches the market, clinicians will face a new decision matrix: which GLP-1 therapy, among a growing array of options, best fits each individual patient